Receptor News and Research

RSS

Merck undergoes restructuring after Schering-Plough merger

Richard T. Clark, chairman, president and chief executive officer of Merck & Co., Inc. (NYSE: MRK) today announced a new organizational structure and named top management and senior leaders for the new Merck effective upon completion of the merger of Merck & Co., Inc. and Schering-Plough Corporation. Mr. Clark was named CEO of the combined company when the merger agreement was signed in March.

31 Aug 2009

Study on basic mechanisms that control fertility in worms may help to know how some woman regain their fertility after cancer treatment

Scientific dogma has long asserted that females are born with their entire lifetime's supply of eggs, and once they're gone, they're gone. New findings by researchers at Fred Hutchinson Cancer Research Center, published online Aug. 27 in Science, suggest that in nematode worms, at least, this does not hold true.

28 Aug 2009

Comprehensive review on the pharmacology of sigma receptors published in Journal of Pharmacology Therapeutics

Anavex Life Sciences Corp. ("ANAVEX" or the "Company") reports the publication of a comprehensive review of the pharmacology of sigma receptors and their possible clinical application in the peer-reviewed Journal of Pharmacology Therapeutics.

28 Aug 2009

New genetic mechanism to control body's fat-building process identified

At a time of alarming increases in obesity and associated diseases -- and fiery debates about the cost of health care -- a UCF research team has identified a new genetic mechanism that controls the body's fat-building process.

27 Aug 2009

Relationship between the CD14 variation and the formation of portal lymphoid aggregates discovered

It is still unknown why the natural history of chronic disease caused by hepatitis C virus (HCV), which currently infects 3% of the world's population, varies from mild in some patients to rapidly progressing in others. Age, sex, alcohol consumption and liver sensitivity to gut-derived bacterial endotoxins, were the early factors defined to enhance the risk of fibrosis progression.

27 Aug 2009

Cannabis chemicals halt prostate cancer growth

Active chemicals in cannabis have been shown to halt prostate cancer cell growth according to research published in the British Journal of Cancer.

26 Aug 2009

Herbalscience research throws light on causes of allergic rhinitis

Most people might think of nettle as simply a common and aggressive weed that can sting and cause skin irritation. But nettle has also been used for hundreds of years to treat seasonal allergies and other inflammatory diseases, although the precise nature of its anti-inflammatory effect was unknown. Now, scientists with HerbalScience have identified specific bioactives in nettle leaf extracts that inhibit in vitro receptors and enzymes known to be key in generating symptoms of allergic rhinitis, or hay fever.

26 Aug 2009

DAS181 inhibits H5N1 Influenza lung virus infection of human lung tissues

NexBio, Inc. announced today the publication "DAS181 Inhibits H5N1 Influenza Lung Virus Infection of Human Lung Tissues" in the September, 2009 issue of the journal Antimicrobial Agents and Chemotherapy (AAC).

26 Aug 2009

Modest decline for hypertension drug industry over the next decade

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that despite generic erosion of many branded agents -- most notably Novartis's Diovan -- the hypertension drug market will experience only modest decline over the next decade.

26 Aug 2009

Tamoxifen drug poses increased risk of developing ER negative breast cancer

While long-term tamoxifen use among breast cancer survivors decreases their risk of developing the most common, less aggressive type of second breast cancer, such use is associated with a more than four-fold increased risk of a more aggressive, difficult-to-treat type of cancer in the breast opposite, or contralateral, to the initial tumor.

26 Aug 2009

Cytrx’s study offers a better perception of arimoclomol's mechanism of action in induced animal stroke

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that study results demonstrated that arimoclomol exhibited both statistically significant neuroprotective and neuroregenerative effects in brain cells of animals induced with stroke, offering important insights into this drug candidate’s mechanism of action.

25 Aug 2009

Portola Pharmaceuticals' investigational antiplatelet drug elinogrel featured at the ESC Congress 2009

Portola Pharmaceuticals, Inc. today announced two oral presentations at the European Society of Cardiology (ESC) Congress 2009 in Barcelona, Spain, that will feature its investigational antiplatelet drug elinogrel, a P2Y12 ADP receptor antagonist that is currently in Phase II clinical development with Novartis, Portola's development and commercialization partner.

25 Aug 2009

Karo Bio collaborates with Wyeth for treating inflammatory diseases

The Swedish biotech company Karo Bio today announced that beginning September 1, 2009, Wyeth will take on all future research and development activities under the drug discovery collaboration between the parties.

25 Aug 2009

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and Neurogen Corporation (NASDAQ:NRGN) announced today they have entered into a definitive merger agreement under which Ligand will acquire Neurogen. Under the transaction, Neurogen stockholders will receive an estimated $11 million in Ligand common stock and will be granted Contingent Value Rights (“CVRs”) under four CVR agreements.

25 Aug 2009

INSERM researchers engineer a chimeric protein that improves stem cell engraftment

Researchers at INSERM (France) have engineered a chimeric protein that increases cell survival, migration and proliferation to improve stem cell engraftment. The results, which appear in the September 2009 issue of Experimental Biology and Medicine, show that TAT-Tpr-Met, a cell permeable form of the hepatocyte growth factor receptor can increase the number of hepatic stem cells integrated into the liver of the mouse.

24 Aug 2009

Two key circuits for controlling the cell's ability identified by UCSF researchers

UCSF researchers have identified the two key circuits that control a cell's ability to adapt to changes in its environment, a finding that could have applications ranging from diabetes and autoimmune research to targeted drug development for complex diseases.

24 Aug 2009

Tiny filaments extending from cells may play a role in common malignant brain tumors

UCSF scientists have discovered that a tiny filament extending from cells, until recently regarded as a remnant of evolution, may play a role in the most common malignant brain tumor in children.

24 Aug 2009

Discovery of genetic biomarkers enable targeted personalised medication for Colorectal cancer

Colorectal cancer (CRC) is the second leading cause of cancer-related death in the Western world. Fortunately physicians today have an abundance of drug therapies available to improve survival length for more advanced cancer patients. Now the discovery of genetic biomarkers relevant to CRC means that targeted personalised medication is increasingly common.

24 Aug 2009

Cannabis chemicals stop prostate cancer growth

Active chemicals in cannabis have been shown to halt prostate cancer cell growth according to research published in the British Journal of Cancer today.

21 Aug 2009

UT Southwestern Medical Center: Human gut bacteria ward off Toxoplasma gondii

Immunology researchers at UT Southwestern Medical Center have found that bacteria present in the human gut help initiate the body's defense mechanisms against Toxoplasma gondii, the parasite responsible for toxoplasmosis.

20 Aug 2009

Receptor News and Research

Merck undergoes restructuring after Schering-Plough merger

Study on basic mechanisms that control fertility in worms may help to know how some woman regain their fertility after cancer treatment

Comprehensive review on the pharmacology of sigma receptors published in Journal of Pharmacology Therapeutics

New genetic mechanism to control body's fat-building process identified

Relationship between the CD14 variation and the formation of portal lymphoid aggregates discovered

Cannabis chemicals halt prostate cancer growth

Herbalscience research throws light on causes of allergic rhinitis

DAS181 inhibits H5N1 Influenza lung virus infection of human lung tissues

Modest decline for hypertension drug industry over the next decade

Tamoxifen drug poses increased risk of developing ER negative breast cancer

Cytrx’s study offers a better perception of arimoclomol's mechanism of action in induced animal stroke

Portola Pharmaceuticals' investigational antiplatelet drug elinogrel featured at the ESC Congress 2009

Karo Bio collaborates with Wyeth for treating inflammatory diseases

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

INSERM researchers engineer a chimeric protein that improves stem cell engraftment

Two key circuits for controlling the cell's ability identified by UCSF researchers

Tiny filaments extending from cells may play a role in common malignant brain tumors

Discovery of genetic biomarkers enable targeted personalised medication for Colorectal cancer

Cannabis chemicals stop prostate cancer growth

UT Southwestern Medical Center: Human gut bacteria ward off Toxoplasma gondii

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News